Back to Search Start Over

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

Authors :
Caitlin Stashwick
Mark H. O'Hara
Janos L. Tanyi
Andrew R. Haas
Source :
Immunotherapy. 8:449-460
Publication Year :
2016
Publisher :
Future Medicine Ltd, 2016.

Abstract

Mesothelin is a promising target for immune-based therapy, specifically for mesothelioma and pancreatic and ovarian cancers that have high levels of mesothelin expression. Many preclinical and clinical studies that target tumors with high mesothelin expression with antibodies, immunotoxins, antibody–drug conjugates and vaccines have shown the potential of mesothelin as a target. Studies of T cells genetically modified with chimeric antigen receptors (CAR) report significant efficacy in hematologic malignancies, and antimesothelin CAR T cells are currently being investigated in clinical studies. Here we outline the rationale for using mesothelin as a target for immunotherapy, review the clinical and preclinical studies evaluating mesothelin-directed therapies and explore the promise of CAR T cells directed against mesothelin for immunotherapy in the future.

Details

ISSN :
17507448 and 1750743X
Volume :
8
Database :
OpenAIRE
Journal :
Immunotherapy
Accession number :
edsair.doi.dedup.....cf1ff47f6b77d91b3ea9b2cb76a32cc6
Full Text :
https://doi.org/10.2217/imt.16.4